Table 5.
Summary of the economic analysis results using base case costs
| Usual care | STS HM | STS HH | TM | |
|---|---|---|---|---|
| Total costs | ||||
| Including Home-HF12 | £8478 | £8965 | £9574 | £9437 |
| Excluding Home-HF12 | £8478 | £9087 | £9658 | £9665 |
| Total QALYs | ||||
| Including Home-HF12 | 2.4137 | 2.3633 | 2.4950 | 2.4944 |
| Excluding Home-HF12 | 2.4137 | 2.4043 | 2.5230 | 2.5847 |
| ICERs | ||||
| Including Home-HF12 | Dominated | £228 035* | £11 873 | |
| Excluding Home-HF12 | Dominated | Extendedly dominated | £6942* | |
| Probability of cost-effectiveness (%) | ||||
| Including Home-HF12 | 6 | 19 | 35 | 40 |
| Excluding Home-HF12 | 1 | 7 | 19 | 73 |
*Last strategy in the cost-effectiveness frontier.
ICERs, incremental cost-effectiveness ratios; QALYs, quality adjusted life years; STS HH, structured telephone support via human to human contact; STS HM, structured telephone support via human to machine interface; TM, telemonitoring.